5 Jim Cramer Stock Picks this Week

2. Biohaven Ltd. (NYSE:BHVN)

Upside Potential: 46%
Price target: $28

Biohaven Ltd. (NYSE:BHVN) is one stock Cramer believes has significant upside potential despite the company suffering major setbacks. The US Food and Drug Administration did not approve the company’s Troriluzole candidate drug for treating an Ultra rare neurodegenerative disorder on failing to meet its primary endpoint.

While Biohaven Ltd. (NYSE:BHVN) has pulled back nearly 20% from its 2023 highs, Cramer remains confident about its long-term prospects. He is especially confident about its Nurtec drug, a medication for migraine. The average consensus price target on the stock is $28, implying a 46% upside potential.

Follow Biohaven Ltd.